Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.00 | 54.60 | -0.61% |
| CAC 40 | 7,769.21 | 95.86 | -1.22% |
| DAX 40 | 25,104.36 | 344.83 | -1.35% |
| Dow JONES (US) | 51,179.87 | 341.41 | -0.66% |
| FTSE 100 | 10,458.50 | 83.19 | -0.79% |
| HKSE | 24,047.13 | 83.37 | -0.35% |
| NASDAQ | 27,538.69 | 61.20 | -0.22% |
| Nikkei 225 | 69,373.40 | 662.31 | -0.95% |
| NZX 50 Index | 13,651.88 | 32.16 | -0.24% |
| S&P 500 | 7,801.77 | 17.16 | -0.22% |
| S&P/ASX 200 | 8,677.30 | 50.40 | -0.58% |
| SSE Composite Index | 3,833.59 | 8.60 | -0.22% |